Nat Prod Sci.  2016 Dec;22(4):293-298. 10.20307/nps.2016.22.4.293.

Effects of Triterpenoids from Luvunga scandens on Cytotoxic, Cell Cycle Arrest and Gene Expressions in MCF-7 Cells

• Taher M
• Al-Zikri P
• Susanti D
• Ichwan SJ
• Rezali MF

• KMID: 2366699
• DOI: http://doi.org/10.20307/nps.2016.22.4.293

Abstract

Plant-derived triterpenoids commonly possesses biological properties such as anti-inflammatory, anti-microbial, anti-viral and anti-cancer. Luvunga scandens is one of the plant that produced triterpenoids. The aims of the study was to analyze cell cycle profile and to determine the expression of p53 unregulated modulator of apoptosis (PUMA), caspase-8 and caspase-9 genes at mRNA level in MCF-7 cell line treated with two triterpenoids, flindissol (1) and 3-oxotirucalla-7,24-dien-21-oic-acid (2) isolated from L. scandens. The compounds were tested for cell cycle analysis using flow cytometer and mRNA expression level using quantitative RT-PCR. The number of MCF-7 cells population which distributed in Sub G1 phase after treated with compound 1 and 2 were 7.7 and 9.3% respectively. The evaluation of the expression of genes showed that both compounds exhibited high level of expression of PUMA, caspase-8 and caspase-9 as normalized to β-actin via activation of those genes. In summary, the isolated compounds of L. scandens plant showed promising anticancer properties in MCF-7 cell lines.

Keyword

Luvunga scandens; Triterpenoids; MCF-7; Gene expressions; Flow cytometry

MeSH Terms

Apoptosis
Caspase 8
Caspase 9
Cell Cycle Checkpoints*
Cell Cycle*
Flow Cytometry
G1 Phase
Gene Expression*
MCF-7 Cells*
Plants
Puma
RNA, Messenger
Caspase 8
Caspase 9
RNA, Messenger

Figure

• 

  Fig. 1 (a) Chemical structure of flindissol (compound 1) and (b) 3-oxotirucalla-7,24-dien-21-oic acid (compound 2).

• 

  Fig. 2 DNA content frequency histogram of MCF-7 cells treated with IC50 value of compound 1(a), compound 2(b), doxorubicin (c) for 24 h and untreated cells (d). The cells were stained with PI and analyzed by flow cytometer for DNA content. Markers 1, 2, 3 and 4 represent G0/G1, S, G2/M and sub G1 (apoptotic cells) phases, respectively.

• 

  Fig. 3 Effects of compounds 1 and 2 on PUMA (a), caspase-8 (b) and caspase-9 (c) mRNA level. mRNA level of all genes were normalized to β-actin mRNA and fold changes expressed relative to the untreated control. Value shows represent mean ± SE using Student's t-test (*p < 0.05, **p < 0.01, ***p < 0.001).

Reference

1. DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. CA Cancer J Clin. 2016; 66:31–42.

2. Hortobagyi GN, de la Garza Salazar J, Pritchard K, Amadori D, Haidinger R, Hudis CA, Khaled H, Liu MC, Martin M, Namer M, O'Shaughnessy JA, Shen ZZ, Albain KS. ABREAST Investigators. Clin Breast Cancer. 2005; 6:391–401.

3. O'Donovan N, Crown J, Stunell H, Hill AD, McDermott E, O'Higgins N, Duffy MJ. Clin Cancer Res. 2003; 9:738–742.

4. Simstein R, Burow M, Parker A, Weldon C, Beckman B. Exp Biol Med. 2003; 228:995–1003.

5. Al-Zikri PNH, Taher M, Susanti D, Rezali MF, Read RW, Sohrab MH, Hasan CM, Ahmad F. Rev Bras Farmacogn. 2014; 24:561–564.

6. Yu J, Zhang L. Oncogene. 2009; 27:S71–S83.

7. Yu J, Yue W, Wu B, Zhang L. Clin Cancer Res. 2006; 12:2928–2936.

8. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. Mol Cell. 2001; 7:673–682.

9. Jänicke RU. Breast Cancer Res Treat. 2009; 117:219–221.

10. Chaabane W, User SD, El-Gazzah M, Jaksik R, Sajjadi E, Rzeszowska-Wolny J, Łos MJ. Arch Immunol Ther Exp. 2013; 61:43–58.

11. Crighton D, Wilkinson S, O'Prey J, Syed N, Smith P, Harrison PR, Gasco M, Garrone O, Crook T, Ryan KM. Cell. 2006; 126:121–134.